Vaziri-Harami R, Delkash P. Can l-carnitine reduce post-COVID-19 fatigue?
Ann Med Surg (Lond) 2021;
73:103145. [PMID:
34925826 PMCID:
PMC8667465 DOI:
10.1016/j.amsu.2021.103145]
[Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 12/01/2021] [Accepted: 12/01/2021] [Indexed: 12/16/2022] Open
Abstract
A significant number of patients infected with the new coronavirus suffer from chronic fatigue syndrome after COVID-19, and their symptoms may persist for months after the infection. Nevertheless, no particular treatment for post-disease fatigue has been found. At the same time, many clinical trials have shown the effectiveness of l-carnitine in relieving fatigue caused by the treatment of diseases such as cancer, MS, and many other diseases. Therefore, it can be considered as a potential option to eliminate the effects of fatigue caused by COVID-19, and its consumption is recommended in future clinical trials to evaluate its effectiveness and safety.
The coronavirus disease is a viral infection that could induce different respiratory.
A significant number of patients infected with the new coronavirus suffer from chronic fatigue.
Clinical trials have shown the effectiveness of L-carnitine in relieving fatigue.
Collapse